ACRS

ACRS

Last Updated:

Q3 '20

Aclaris Therapeutics Inc.

To be a champion for underserved conditions takes great ideas and great passion. Welcome to Aclaris, a biopharmaceutical company that strives to translate scientific discovery into everyday victories in immuno-inflammatory conditions.

Cash

$68.1M

Burn Rate (Qtr)

$10.7M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

ATI-450

Cytokine Release Syndrom in COVID-19 Patients

Phase 2

H2 2020

ATI-1777

Atopic Dermatitis

Phase 2a

TBD

ATI-450

Rheumatoid Arthritis

Phase 2a

H1 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon